The contractor shall coordinate, maintain and manage nichd participating sites for impaact 2041: phase I/II study of the pharmacokinetics and safety of glecaprevir/pibrentasvir initiated in…
Active Awarded
- Contract number
- 75N94025F00001
- Awardee
-
Westat, Inc. UEI NVUWAFWQ57S5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,125,154
Award facts
- Contract value 100% obligated
- $1,125,154.00 Current and potential, with all options
- Completion date 49% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Child Health and Human Development (NICHD) to Westat, Inc., a prominent professional services firm. The contract, with a ceiling value of $1,125,154.00, requires Westat to coordinate, maintain, and manage NICHD participating sites for IMPAACT 2041, a Phase I/II study on the pharmacokinetics and safety of the hepatitis C drug combination of glecaprevir/pibrentasvir initiated in pregnancy, with and without HIV. This contract is part of a larger $175 million Indefinite Delivery Vehicle (IDV) between NICHD and Westat for international and domestic pediatric HIV studies. The contract does not have a set-aside designation and is scheduled for completion by July 31, 2028.
Description
The contractor shall coordinate, maintain and manage nichd participating sites for impaact 2041: phase I/II study of the pharmacokinetics and safety of glecaprevir/pibrentasvir initiated in pregnancy in people with hepatitis C with and without HIV.
Quick answers
Who was awarded contract 75N94025F00001?
75N94025F00001 was awarded to Westat, Inc. by National Institute of Child Health and Human Development (National Institutes of Health) on March 7, 2025.
How much is contract 75N94025F00001 worth?
The government has obligated $1,125,154 on 75N94025F00001.
Is contract 75N94025F00001 an order under another contract?
Yes. 75N94025F00001 is a delivery order under 75N94023D00001, an indefinite delivery contract.
Was contract 75N94025F00001 competed?
The extent of competition for 75N94025F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award